UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma

Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical and biomedical analysis Vol. 138; pp. 223 - 230
Main Authors Simiele, Marco, Ariaudo, Alessandra, De Nicolò, Amedeo, Favata, Fabio, Ferrante, Martina, Carcieri, Chiara, Bonora, Stefano, Di Perri, Giovanni, D’Avolio, Antonio
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 10.05.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation protocol, suitable for clinical routine.•The method has been tested on real-life specimens with good results. Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC–MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC–MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.
AbstractList Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.
Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful UHPLC–MS/MS method to quantify a wide panel of antiretroviral drugs.•Validated method following FDA guidelines.•Fast and cheap protein precipitation protocol, suitable for clinical routine.•The method has been tested on real-life specimens with good results. Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC–MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity® UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC–MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.
Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties, thus making the use of therapeutic drug monitoring for these drugs not useful. This lack of information is partially due to the absence of an high-throughput method for their simultaneous quantification together with other antiretroviral drugs. In this work, we describe the development and validation of a new UPLC-MS/MS method to quantify these drugs, together with other fourteen antiretroviral agents, in human plasma. One hundred microliters of plasma samples were added with internal standard (6,7-Dimethyl- 2,3-di(2-pyridyl) quinoxaline), underwent a simple protein precipitation with methanol:acetonitrile (50:50v/v) followed by sample dilution with water. Chromatographic separation was performed on a Acquity UPLC HSS T3 column (150mm x 2.1mm I.D) with a particle size of 1.8μm and compounds were detected with a tandem mass detector, monitoring two ion transitions for each drugs. The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively. Accuracy and precision inter/intra-day were below 15% for all drugs, in accordance to Food and Drug Administration guidelines requirements. The UPLC-MS/MS method reported here could be used routinely to monitor plasma concentrations of antiviral drugs, including RPV, DTG and EVG.
Author D’Avolio, Antonio
Simiele, Marco
Ariaudo, Alessandra
Carcieri, Chiara
Bonora, Stefano
De Nicolò, Amedeo
Favata, Fabio
Ferrante, Martina
Di Perri, Giovanni
Author_xml – sequence: 1
  givenname: Marco
  surname: Simiele
  fullname: Simiele, Marco
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 2
  givenname: Alessandra
  surname: Ariaudo
  fullname: Ariaudo, Alessandra
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 3
  givenname: Amedeo
  surname: De Nicolò
  fullname: De Nicolò, Amedeo
  email: amedeo.denicolo@unito.it
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 4
  givenname: Fabio
  surname: Favata
  fullname: Favata, Fabio
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 5
  givenname: Martina
  surname: Ferrante
  fullname: Ferrante, Martina
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 6
  givenname: Chiara
  surname: Carcieri
  fullname: Carcieri, Chiara
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 7
  givenname: Stefano
  surname: Bonora
  fullname: Bonora, Stefano
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 8
  givenname: Giovanni
  surname: Di Perri
  fullname: Di Perri, Giovanni
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
– sequence: 9
  givenname: Antonio
  surname: D’Avolio
  fullname: D’Avolio, Antonio
  organization: University of Turin, Department of Medical Sciences,2 Laboratory of Clinical Pharmacology and Pharmacogenetics,3 Amedeo di Savoia Hospital, CorsoSvizzera 164, 10149, Turin, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28219799$$D View this record in MEDLINE/PubMed
BookMark eNp9UsuO0zAUtdAgpjPwAyyQlyyajO2ksSOxQRUvqSOQhpHYWY5z07pK7I7tFLHjH_hDFnwHTh-bWczKutfnnGufe67QhXUWEHpNSU4JrW62-XbXqJwRynPCckLYMzSjghcZq8ofF2hGeEEzTsTiEl2FsCWELGhdvkCXTDBa87qeoX_331bLv7__3N7d3N7hAeLGtbhzHscN4GCGsY_KghsDfhiVjaYzWkXjLHZdgngAbOEnnm48RO_2xqset35chzluXT9GWHuVunMM_d6cq0RosTf9zqTCWJgfGi7NnAYbHwHsY1G1BhsD3vXpLdo1RpsQVTwpRWcPuo1zIYIP2Fi8GQdlE16FQb1EzzvVB3h1Oq_R_ccP35efs9XXT1-W71eZLhmLWQVVrUpRQ82KmgIXrG00tLVSnFGoigWvuq5VTNQVobTlQlXAaSGaqtQKyq64Rm-PujvvHkYIUQ4maOj7o4kybYdUpRCEJOibE3RsBmjlzptB-V_yvJsEEEeA9i4ED53UJh7Mj16ZXlIipxjIrZxiIKcYSMJkikGiskfUs_qTpHdHEiSD9ga8DNqATf9Pa9BRts48Rf8PmObT9A
CitedBy_id crossref_primary_10_1093_jac_dky508
crossref_primary_10_1002_jssc_202100152
crossref_primary_10_1093_jat_bkaf016
crossref_primary_10_1111_bcp_15538
crossref_primary_10_2174_1573412914666180621110432
crossref_primary_10_1007_s10337_024_04314_2
crossref_primary_10_1186_s12981_021_00338_y
crossref_primary_10_1002_sscp_202400168
crossref_primary_10_1111_bcp_13552
crossref_primary_10_1016_j_jpba_2019_113057
crossref_primary_10_1002_sscp_201800043
crossref_primary_10_1007_s40262_020_00916_9
crossref_primary_10_1007_s11696_019_00771_4
crossref_primary_10_15369_sujms_32_91
crossref_primary_10_1016_j_trac_2023_116964
crossref_primary_10_1134_S1061934821100129
crossref_primary_10_1016_j_jchromb_2024_124275
crossref_primary_10_1007_s40261_018_0739_9
crossref_primary_10_1371_journal_pone_0246994
crossref_primary_10_1002_bmc_4274
crossref_primary_10_1093_jac_dkae080
crossref_primary_10_1016_j_ijms_2020_116370
crossref_primary_10_3390_antiox14010082
crossref_primary_10_1002_slct_202203174
crossref_primary_10_1002_bmc_4170
crossref_primary_10_1093_jac_dkx461
crossref_primary_10_3390_molecules26082123
crossref_primary_10_3390_ph14010012
crossref_primary_10_53879_id_56_10_11796
crossref_primary_10_1016_j_talanta_2020_121862
crossref_primary_10_1080_10408347_2021_1908111
crossref_primary_10_1016_j_ijantimicag_2024_107200
crossref_primary_10_1080_10408347_2022_2039094
crossref_primary_10_1016_j_aca_2019_01_015
crossref_primary_10_1016_j_jchromb_2018_12_008
crossref_primary_10_3390_diagnostics13020295
crossref_primary_10_52711_0974_360X_2022_00893
crossref_primary_10_1556_1326_2018_00459
crossref_primary_10_1002_bmc_5708
crossref_primary_10_1080_10408347_2022_2080493
crossref_primary_10_1002_jssc_202201067
crossref_primary_10_1016_j_talanta_2018_01_012
crossref_primary_10_1016_j_diamond_2021_108332
crossref_primary_10_1016_j_cca_2023_117678
crossref_primary_10_1016_j_jpba_2020_113119
crossref_primary_10_1093_jac_dkaa094
crossref_primary_10_1016_j_jpba_2017_07_003
Cites_doi 10.1002/bmc.2765
10.1016/j.jpba.2013.08.002
10.1016/S0140-6736(12)60918-0
10.1517/14740331003767395
10.1097/QAI.0b013e31824d006e
10.1097/00002030-200203001-00002
10.2152/jmi.60.35
10.1016/j.jpba.2013.02.025
10.1038/ijos.2013.76
10.1007/s40265-014-0256-y
10.1016/S0140-6736(12)60917-9
10.1097/FTD.0b013e318189596d
10.1002/jms.3200
10.1016/j.jchromb.2006.10.030
10.1007/s11904-014-0207-y
10.1016/j.jpba.2015.08.004
10.1016/j.jchromb.2010.03.036
ContentType Journal Article
Copyright 2017
Copyright © 2017. Published by Elsevier B.V.
Copyright_xml – notice: 2017
– notice: Copyright © 2017. Published by Elsevier B.V.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jpba.2017.02.002
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-264X
EndPage 230
ExternalDocumentID 28219799
10_1016_j_jpba_2017_02_002
S0731708516314534
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
5VS
7-5
71M
8P~
9JM
9JN
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARLI
AATCM
AAXUO
ABFRF
ABJNI
ABMAC
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADECG
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AFZHZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJSZI
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FLBIZ
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M34
M36
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
RNS
ROL
RPZ
SCC
SCH
SDF
SDG
SDP
SES
SPC
SPCBC
SSK
SSP
SSZ
T5K
TEORI
YK3
~G-
29L
53G
AAQXK
AATTM
AAXKI
AAYWO
AAYXX
ABFNM
ABWVN
ABXDB
ACNNM
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AHHHB
AIGII
AIIUN
AJQLL
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
BNPGV
CITATION
FEDTE
FGOYB
G-2
HMT
HMU
HVGLF
HZ~
R2-
SCB
SEW
SPT
SSH
WUQ
XPP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFKBS
ID FETCH-LOGICAL-c422t-6e69a489e92391e782dbced9aa721e63576ffda2896011d78a6e7138b64cae4f3
IEDL.DBID .~1
ISSN 0731-7085
1873-264X
IngestDate Tue Aug 05 11:03:17 EDT 2025
Wed Feb 19 02:00:02 EST 2025
Thu Apr 24 23:07:19 EDT 2025
Tue Jul 01 01:17:48 EDT 2025
Fri Feb 23 02:25:39 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Tandem mass spectrometry
Antiretrovirals
Liquid chromatography
Reverse phase
Protein precipitation
HAART
Language English
License Copyright © 2017. Published by Elsevier B.V.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-6e69a489e92391e782dbced9aa721e63576ffda2896011d78a6e7138b64cae4f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 28219799
PQID 1870648800
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1870648800
pubmed_primary_28219799
crossref_citationtrail_10_1016_j_jpba_2017_02_002
crossref_primary_10_1016_j_jpba_2017_02_002
elsevier_sciencedirect_doi_10_1016_j_jpba_2017_02_002
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-05-10
PublicationDateYYYYMMDD 2017-05-10
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-10
  day: 10
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of pharmaceutical and biomedical analysis
PublicationTitleAlternate J Pharm Biomed Anal
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Younai (bib0005) 2013; 5
De Nicolò, Abdi, Boglione, Baiett, Allegra, Di Perri, D'Avolio (bib0115) 2015; 115
Djerada, Feliu, Tournois, Vautier, Binet, Robinet, Marty, Gozalo, Lamiable, Millart (bib0070) 2013; 86
FDA (bib0095) 2013
Bourgeois, Womack, Newsom, Caldwell (bib0015) 2012; 24
Back, Gatti, Fletcher, Garaffo, Haubrich, Hoetelmans, Kurowski, Luber, Merry, Perno (bib0045) 2002; 16
Sax, DeJesus, Mills, Zolopa, Cohen, Wohl, Gallant, Liu, Zhong, Yale, White, Kearney, Szwarcberg, Quirk, Cheng (bib0030) 2012; 379
Shibata, Takahashi, Yoshino, Kuwahara, Nomura, Yokomaku, Sugiura (bib0085) 2013; 60
Cohen, Molina, Cahn, Clotet, Fourie, Grinsztejn, Wu, Johnson, Saag, Supparatpinyo, Crauwels, Lefebvre, Rimsky, Vanveggel, Williams, Boven (bib0025) 2012; 60
Liu, Ma, Zhang (bib0050) 2010; 9
Aouri, Calmy, Hirschel, Telenti, Buclin, Cavassini, Rauch, Decosterd (bib0055) 2013; 48
McCormack (bib0040) 2014; 74
D'Avolio, Baietto, Siccardi, Sciandra, Simiele, Oddone, Bonora, Di Perri (bib0100) 2008; 30
EMA (bib0090) 2011
Svicher, Ceccherini-Silberstein, Antinori, Aquaro, Perno (bib0010) 2014; 11
Gupta, Guttikar, Patel, Shrivastav, Sanyal (bib0080) 2014
D'Avolio, De Nicolo, Agnesod, Simiele, Mohamed Abdi, Dilly Penchala, Boglione, Cariti, Di Perri (bib0110) 2013; 78–79
Ford, Lee, Andrieux-Meyer, Calmy (bib0020) 2011; 3
Burugula, Pilli, Makula, Lodagala, Kandhagatla (bib0065) 2012; 27
Else, Watson, Tjia, Hughes, Siccardi, Khoo, Back (bib0075) 2010; 878
DeJesus, Rockstroh, Henry, Molina, Gathe, Ramanathan, Wei, Yale, Szwarcberg, White, Cheng, Kearney (bib0035) 2012; 379
Bennetto-Hood, Tabolt, Savina, Acosta (bib0060) 2013; 945–946
D'Avolio, Sciandra, Siccardi, Baietto, de Requena, Bonora, Di Perri (bib0105) 2007; 848
Bourgeois (10.1016/j.jpba.2017.02.002_bib0015) 2012; 24
D'Avolio (10.1016/j.jpba.2017.02.002_bib0100) 2008; 30
Aouri (10.1016/j.jpba.2017.02.002_bib0055) 2013; 48
Gupta (10.1016/j.jpba.2017.02.002_bib0080) 2014
Ford (10.1016/j.jpba.2017.02.002_bib0020) 2011; 3
EMA (10.1016/j.jpba.2017.02.002_bib0090) 2011
Sax (10.1016/j.jpba.2017.02.002_bib0030) 2012; 379
FDA (10.1016/j.jpba.2017.02.002_bib0095) 2013
Djerada (10.1016/j.jpba.2017.02.002_bib0070) 2013; 86
Younai (10.1016/j.jpba.2017.02.002_bib0005) 2013; 5
Burugula (10.1016/j.jpba.2017.02.002_bib0065) 2012; 27
McCormack (10.1016/j.jpba.2017.02.002_bib0040) 2014; 74
Else (10.1016/j.jpba.2017.02.002_bib0075) 2010; 878
Shibata (10.1016/j.jpba.2017.02.002_bib0085) 2013; 60
Cohen (10.1016/j.jpba.2017.02.002_bib0025) 2012; 60
Svicher (10.1016/j.jpba.2017.02.002_bib0010) 2014; 11
DeJesus (10.1016/j.jpba.2017.02.002_bib0035) 2012; 379
Bennetto-Hood (10.1016/j.jpba.2017.02.002_bib0060) 2013; 945–946
Liu (10.1016/j.jpba.2017.02.002_bib0050) 2010; 9
D'Avolio (10.1016/j.jpba.2017.02.002_bib0110) 2013; 78–79
De Nicolò (10.1016/j.jpba.2017.02.002_bib0115) 2015; 115
D'Avolio (10.1016/j.jpba.2017.02.002_bib0105) 2007; 848
Back (10.1016/j.jpba.2017.02.002_bib0045) 2002; 16
References_xml – volume: 379
  start-page: 2429
  year: 2012
  end-page: 2438
  ident: bib0035
  article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 non-inferiority trial
  publication-title: Lancet
– volume: 60
  start-page: 33
  year: 2012
  end-page: 42
  ident: bib0025
  article-title: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
  publication-title: J. Acquir. Immune Defic. Syndr.
– volume: 27
  start-page: 172
  year: 2012
  end-page: 178
  ident: bib0065
  article-title: Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma
  publication-title: Biomed. Chromatogr.
– volume: 11
  start-page: 186
  year: 2014
  end-page: 194
  ident: bib0010
  article-title: Understanding HIV compartments and reservoirs
  publication-title: Curr. HIV/AIDS Rep.
– volume: 878
  start-page: 1455
  year: 2010
  end-page: 1465
  ident: bib0075
  article-title: Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– year: 2011
  ident: bib0090
  article-title: Guideline on Bioanalytical Method Validation
– volume: 848
  start-page: 374
  year: 2007
  end-page: 378
  ident: bib0105
  article-title: A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– year: 2013
  ident: bib0095
  article-title: Guidance for Industry: Bioanalytical Method Validation
– volume: 74
  start-page: 1241
  year: 2014
  end-page: 1252
  ident: bib0040
  article-title: Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults
  publication-title: Drugs
– volume: 115
  start-page: 443
  year: 2015
  end-page: 449
  ident: bib0115
  article-title: UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells
  publication-title: J. Pharm. Biomed. Anal.
– volume: 3
  start-page: 35
  year: 2011
  end-page: 44
  ident: bib0020
  article-title: Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
  publication-title: HIV AIDS (Auckl)
– volume: 379
  start-page: 2439
  year: 2012
  end-page: 2448
  ident: bib0030
  article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
  publication-title: Lancet
– volume: 5
  start-page: 191
  year: 2013
  end-page: 199
  ident: bib0005
  article-title: Thirty years of the human immunodeficiency virus epidemic and beyond
  publication-title: Int. J. Oral Sci.
– volume: 48
  start-page: 616
  year: 2013
  end-page: 625
  ident: bib0055
  article-title: A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients
  publication-title: J. Mass Spectrom.
– volume: 60
  start-page: 35
  year: 2013
  end-page: 40
  ident: bib0085
  article-title: Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations
  publication-title: J. Med. Invest.
– volume: 86
  start-page: 100
  year: 2013
  end-page: 111
  ident: bib0070
  article-title: Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology
  publication-title: J. Pharm. Biomed. Anal.
– volume: 78–79
  start-page: 217
  year: 2013
  end-page: 223
  ident: bib0110
  article-title: A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
  publication-title: J. Pharm. Biomed. Anal.
– volume: 24
  start-page: 12
  year: 2012
  end-page: 15
  ident: bib0015
  article-title: A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing
  publication-title: HIV Clin.
– volume: 30
  start-page: 662
  year: 2008
  end-page: 669
  ident: bib0100
  article-title: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients
  publication-title: Ther. Drug Monit.
– volume: 945–946
  start-page: 225
  year: 2013
  end-page: 232
  ident: bib0060
  article-title: A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– volume: 16
  start-page: S5
  year: 2002
  end-page: 37
  ident: bib0045
  article-title: Therapeutic drug monitoring in HIV infection: current status and future directions
  publication-title: AIDS
– year: 2014
  ident: bib0080
  article-title: Reliable LC-MS/MS assay for the estimation of rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis
  publication-title: Drug Test Anal
– volume: 9
  start-page: 743
  year: 2010
  end-page: 758
  ident: bib0050
  article-title: Therapeutic drug monitoring in highly active antiretroviral therapy
  publication-title: Expert Opin. Drug Saf.
– volume: 27
  start-page: 172
  year: 2012
  ident: 10.1016/j.jpba.2017.02.002_bib0065
  article-title: Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma
  publication-title: Biomed. Chromatogr.
  doi: 10.1002/bmc.2765
– volume: 86
  start-page: 100
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0070
  article-title: Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2013.08.002
– volume: 379
  start-page: 2429
  year: 2012
  ident: 10.1016/j.jpba.2017.02.002_bib0035
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60918-0
– volume: 9
  start-page: 743
  year: 2010
  ident: 10.1016/j.jpba.2017.02.002_bib0050
  article-title: Therapeutic drug monitoring in highly active antiretroviral therapy
  publication-title: Expert Opin. Drug Saf.
  doi: 10.1517/14740331003767395
– volume: 60
  start-page: 33
  year: 2012
  ident: 10.1016/j.jpba.2017.02.002_bib0025
  article-title: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
  publication-title: J. Acquir. Immune Defic. Syndr.
  doi: 10.1097/QAI.0b013e31824d006e
– year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0095
– volume: 16
  start-page: S5
  issue: Suppl. 1
  year: 2002
  ident: 10.1016/j.jpba.2017.02.002_bib0045
  article-title: Therapeutic drug monitoring in HIV infection: current status and future directions
  publication-title: AIDS
  doi: 10.1097/00002030-200203001-00002
– volume: 60
  start-page: 35
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0085
  article-title: Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations
  publication-title: J. Med. Invest.
  doi: 10.2152/jmi.60.35
– year: 2014
  ident: 10.1016/j.jpba.2017.02.002_bib0080
  article-title: Reliable LC-MS/MS assay for the estimation of rilpivirine in human plasma: application to a bioequivalence study and incurred sample reanalysis
  publication-title: Drug Test Anal
– volume: 78–79
  start-page: 217
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0110
  article-title: A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2013.02.025
– volume: 5
  start-page: 191
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0005
  article-title: Thirty years of the human immunodeficiency virus epidemic and beyond
  publication-title: Int. J. Oral Sci.
  doi: 10.1038/ijos.2013.76
– volume: 24
  start-page: 12
  year: 2012
  ident: 10.1016/j.jpba.2017.02.002_bib0015
  article-title: A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing
  publication-title: HIV Clin.
– volume: 3
  start-page: 35
  year: 2011
  ident: 10.1016/j.jpba.2017.02.002_bib0020
  article-title: Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
  publication-title: HIV AIDS (Auckl)
– volume: 74
  start-page: 1241
  year: 2014
  ident: 10.1016/j.jpba.2017.02.002_bib0040
  article-title: Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults
  publication-title: Drugs
  doi: 10.1007/s40265-014-0256-y
– year: 2011
  ident: 10.1016/j.jpba.2017.02.002_bib0090
– volume: 379
  start-page: 2439
  year: 2012
  ident: 10.1016/j.jpba.2017.02.002_bib0030
  article-title: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60917-9
– volume: 30
  start-page: 662
  year: 2008
  ident: 10.1016/j.jpba.2017.02.002_bib0100
  article-title: An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients
  publication-title: Ther. Drug Monit.
  doi: 10.1097/FTD.0b013e318189596d
– volume: 48
  start-page: 616
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0055
  article-title: A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients
  publication-title: J. Mass Spectrom.
  doi: 10.1002/jms.3200
– volume: 945–946
  start-page: 225
  year: 2013
  ident: 10.1016/j.jpba.2017.02.002_bib0060
  article-title: A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
– volume: 848
  start-page: 374
  year: 2007
  ident: 10.1016/j.jpba.2017.02.002_bib0105
  article-title: A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  doi: 10.1016/j.jchromb.2006.10.030
– volume: 11
  start-page: 186
  year: 2014
  ident: 10.1016/j.jpba.2017.02.002_bib0010
  article-title: Understanding HIV compartments and reservoirs
  publication-title: Curr. HIV/AIDS Rep.
  doi: 10.1007/s11904-014-0207-y
– volume: 115
  start-page: 443
  year: 2015
  ident: 10.1016/j.jpba.2017.02.002_bib0115
  article-title: UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2015.08.004
– volume: 878
  start-page: 1455
  year: 2010
  ident: 10.1016/j.jpba.2017.02.002_bib0075
  article-title: Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
  publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  doi: 10.1016/j.jchromb.2010.03.036
SSID ssj0005194
Score 2.3900776
Snippet Typical chromatogram from direct injection of a chemical mix containing all the target analytes at a concentration of 2μg/mL. [Display omitted] •Useful...
Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 223
SubjectTerms Anti-HIV Agents - blood
Anti-HIV Agents - chemistry
Anti-Retroviral Agents - blood
Anti-Retroviral Agents - chemistry
Antiretrovirals
Chromatography, High Pressure Liquid - methods
Cobicistat - blood
Cobicistat - chemistry
HAART
Heterocyclic Compounds, 3-Ring - blood
Heterocyclic Compounds, 3-Ring - chemistry
Humans
Limit of Detection
Liquid chromatography
Protein precipitation
Quinolones - blood
Quinolones - chemistry
Reproducibility of Results
Reverse phase
Rilpivirine - blood
Rilpivirine - chemistry
Ritonavir - blood
Ritonavir - chemistry
Tandem mass spectrometry
Tandem Mass Spectrometry - methods
Title UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma
URI https://dx.doi.org/10.1016/j.jpba.2017.02.002
https://www.ncbi.nlm.nih.gov/pubmed/28219799
https://www.proquest.com/docview/1870648800
Volume 138
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV29btswECaCdOlS9L9um4AFiiy1alOSRWkMjAbujwMDjoFsBElRBQNXViW5QJYi75A3zNDn6B0pJW2BZOhI-kgR5un4nXj3HSFvk2hcpAWTgebKgIOCl4ShToLUKPDGeKa4C6KZHyezVfzpdHK6Q6Z9LgyGVXa239t0Z627nlH3b44qa0dLUE7GETEkEYsnEXKCxjFHLX__848wD-aKIaJwgNJd4oyP8TqrFHIPMe55O8PbDqfbwKc7hI4ekgcdeqSHfoGPyI4pH5ODhaefPh_Sk5tsqmZID-jihpj6_An5tVp8mV5dXM6Xo_mS-trRFEArBRBIG4uxhbI0m21Dv2-lDyJy-0Y3BYjUxlDA4BR_qU2LnyJqWEteb7_Cs3JUYSSegN4hNesftm_BgJzWdl1ZaACmHboOl_gFs9q6BU_630klJnw1tFrDWvRGWY0ot-1mArTq5gX_AFkeGmpL6koNgrxsvsmnZHX04WQ6C7o6D4GOw7ANEpNkMk4zA2AzYwYwS65g-zMpwT01SJiXFEUuwTUE75HlPJWJAd86VUmspYmL6BnZLTeleUEoyyNtikKlHOxMrHQqweXSPNWGZxPJ9ICwfoOF7kjQsRbHWvTRbmcClUKgUohxKEApBuTd9ZjKU4DcKT3p9Ub8pcgCzqg7x73plUzAG47XNn7LBcOraLSz4wF57rXveh3gMDO8mH35n099Re5jK3B0tK_JbltvzR6grFbtu9don9w7_Ph5dvwbHrcumg
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECVS59Beiu51urFAkUst2NSuY2A0cBrbMGAbyI0gKSpQ4MqqJAfIrf_QP-yh39EZUorRAsmhR1EkRYgj8j1x5g0hn0JvlMUZE46KpAaCgoeErgqdWEtgY1EiI-NEM5uHk7X_9SK4OCDjLhYG3Srbtd-u6Wa1bkuG7dsclnk-XIJxsggRQ-gxP_D8B-QQ1amCHjk8OTufzPeeHszkQ8T6DjZoY2esm9dVKVF-iEVWutO9a3-6C3-afej0CXncAkh6Ysf4lBzo4hk5XlgF6psBXe0DquoBPaaLvTb1zXPye72Yjn_9-DlbDmdLatNHU8CtFHAgrXN0LxSF3u5q-n0nrB-RmTq6zaBKpTUFGE7xTqUb_BtRwVjSancJz0rRilF7AkoHVG-u8-4KGqS0yjdlDhcAawemwMR-Qa951QCZ_rdTgTFfNS03MBa1lblCoNu0PQFgNf0CRUChh5rmBTXZBqG-qL-JF2R9-mU1njhtqgdH-a7bOKEOE-HHiQa8mTANsCWVYAGJEMBQNWrmhVmWCmCHQCBZGsUi1ECvYxn6Smg_816SXrEt9GtCWeopnWUyjmCp8aWKBbAuFcVKR0kgmOoT1k0wV60OOqbj2PDO4e2Ko1FwNAo-cjkYRZ98vm1TWhWQe2sHnd3wv2yZwzZ1b7uPnZFx-Mjx5MZOOWd4Go1L7ahPXlnrux0HcGaGZ7NH__nUD-ThZDWb8unZ_PwNeYR3HKNO-5b0mmqn3wHoauT79qP6A09MMUs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=UPLC%E2%80%93MS%2FMS+method+for+the+simultaneous+quantification+of+three+new+antiretroviral+drugs%2C+dolutegravir%2C+elvitegravir+and+rilpivirine%2C+and+other+thirteen+antiretroviral+agents+plus+cobicistat+and+ritonavir+boosters+in+human+plasma&rft.jtitle=Journal+of+pharmaceutical+and+biomedical+analysis&rft.au=Simiele%2C+Marco&rft.au=Ariaudo%2C+Alessandra&rft.au=De+Nicol%C3%B2%2C+Amedeo&rft.au=Favata%2C+Fabio&rft.date=2017-05-10&rft.pub=Elsevier+B.V&rft.issn=0731-7085&rft.eissn=1873-264X&rft.volume=138&rft.spage=223&rft.epage=230&rft_id=info:doi/10.1016%2Fj.jpba.2017.02.002&rft.externalDocID=S0731708516314534
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0731-7085&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0731-7085&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0731-7085&client=summon